Long-acting erythropoietin analog (Bolder BioTechnology)(Long-acting erythropoietin analog (Bolder BioTechnology))

概要

基本信息

药物类型

集落刺激因子

别名-

靶点

EPO receptor

作用方式

激动剂

作用机制

EPO receptor激动剂(促红细胞生成素受体激动剂)

治疗领域

血液及淋巴系统疾病

在研适应症

贫血

非在研适应症-

原研机构

Bolder BioTechnology, Inc.

在研机构

Bolder BioTechnology, Inc.

非在研机构-

权益机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 Long-acting erythropoietin analog (Bolder BioTechnology) 相关的临床结果

登录后查看更多信息

100 项与 Long-acting erythropoietin analog (Bolder BioTechnology) 相关的转化医学

登录后查看更多信息

100 项与 Long-acting erythropoietin analog (Bolder BioTechnology) 相关的专利（医药）

登录后查看更多信息

1

项与 Long-acting erythropoietin analog (Bolder BioTechnology) 相关的文献（医药）

2016-02-01·International Urology and Nephrology4区 · 医学

Effects of long-acting erythropoietin analog darbepoetin-α on adriamycin-induced chronic nephropathy

4区 · 医学

Article

作者: Elserougy, Hanaa ; Handhle, Ahmed ; Eldosoky, Mohamed ; Hussiny, Mahmoud El ; Sarhan, Mohamed ; Sobh, Mohamed A ; Hussein, Abdelaziz M ; El Nashar, Eman M

OBJECTIVESTo study the effects of darbepoetin-α (DPO-α) (erythropoietin analog) on adriamycin (ADR)-induced chronic nephropathy in rats.METHODSSixty-nine male Sprague-Dawley rats divided into 3 groups (23 rats each): negative control group: normal rats received saline as a vehicle; positive control (ADR) group: rats received 2 iv injection of ADR via penile vein at 14-day interval without treatment; and DPO-α group: as ADR group but rats received sc DPO-α (0.3 μg/kg bw) once weekly for 12 weeks. By the end of experiment hemoglobin (Hb) content, serum creatinine, BUN, albumin, triglycerides and cholesterol, urinary protein excretion and kidney injury molecule-1 (KIM-1). GSH, malondialdehyde, caspase-3 expression histopathological and electron microscopic examinations for kidney tissues were done.RESULTSDPO-α significantly improved the animal survival rate and body weight, Hb, serum BUN, triglycerides, cholesterol, and albumin and urinary protein excretion and KIM-1 in urine. Also, administration of DPO-α improved the morphological damage in glomeruli and renal tubules as well as caspase-3 expression and markers of oxidative stress in kidney tissues.CONCLUSIONAdministration of DPO-α alleviates ADR nephropathy and this might due to improvement of Hb content, hyperlipidemia, enhancement of endogenous antioxidants, reduction of apoptosis and tubulointerstitial injury and maintaining the integrity of glomerular membrane.

100 项与 Long-acting erythropoietin analog (Bolder BioTechnology) 相关的药物交易

登录后查看更多信息